Healthcare Industry News:  endoscopy 

Devices Diagnostics Oncology

 News Release - July 13, 2022

Mauna Kea Technologies Announces Publication of a Meta-Analysis Demonstrating Cellvizio’s Significant Role in Detection of Esophageal Dysplasia and Cancer

Results demonstrate a significant increase in the detection rate of neoplasia when Cellvizio is used as an adjunct to the standard of care, underscoring the key role of advanced imaging in slowing the rapid growth of esophageal cancer

Meta-analysis builds on recent data demonstrating that the use of Cellvizio is also associated with lower health services utilization and fewer overall endoscopy procedures

Paris and Boston, July 6, 2022 -- (Healthcare Sales & Marketing Network) -- Mauna Kea Technologies (Euronext: MKEA, ‘Mauna Kea’) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform today announced the peer-reviewed publication of a new meta-analysis in Techniques and Innovations in Gastrointestinal endoscopy (TIGE) entitled “High definition probe-based confocal laser endomicroscopy review and meta-analysis for neoplasia detection in Barrett’s esophagus”1. The study demonstrates that the addition of Cellvizio as an adjunct to guide biopsies provides a significantly higher diagnostic yield for dysplasia and cancer and reduces sampling error compared to random four-quadrant biopsies alone, the standard of care.

Existing endoscopic screening and surveillance methods are insufficient in detecting Barrett’s Esophagus or esophageal cancer, as using the Seattle Protocol standard of care alone is prone to sampling error and poor sensitivity and specificity. At Digestive Disease Week® (DDW) in May 2022, Dr. Bashar Qumseya presented data2 based on roughly 5 million people and showing that, among those ages 45 to 64, esophageal cancer (EAC) rate nearly doubled from 2012 to 2019. Moreover, the prevalence of Barrett's esophagus – the only known precursor to EAC – rose by about 50% in this age group in the same period.

In the TIGE meta-analysis, the authors included 9 studies for a total of 688 patients and 1,299 lesions and assessed the benefits of probe-based CLE (pCLE) as an adjunct to random 4-quadrant biopsies in the surveillance of patients with Barrett's esophagus for dysplasia and early EAC detection. Per-patient pCLE pooled sensitivity, specificity, and negative predictive value were 96%, 93%, and 98%, respectively. Compared to random biopsies, the per-patient pooled absolute and relative detection rate increases of neoplasia with pCLE were significant and equal to 5% and 243%, respectively.

Separately, at the ENDO 2022 World Congress of GI endoscopy in May 2022, the results of a retrospective multi-center chart review3 of 60 patients with Barrett’s esophagus who were referred for endoscopic surveillance or treatment were presented. The authors were examining differences in gastroenterology health services utilization for eight items/services among patients treated using Cellvizio as an adjunct versus standard of care alone. The Cellvizio cohort had 1.04 fewer endoscopies and anesthesia services, 7.49 less biopsy bottles, 1.30 fewer ablations, and 1.46 less brush cytology services. Therefore, the researchers concluded that Cellvizio is associated with an overall lower burden to the healthcare system.

“The results from these studies demonstrate that there are better tools that are easily accessible to physicians who are working to improve the detection rate of screening and surveillance programs, and ultimately reverse the alarming rise in prevalence of esophageal cancer,” said Nicolas Bouvier, Interim Chief Executive Officer of Mauna Kea Technologies. “Better detection rates and a lower utilization of healthcare services make Cellvizio a valuable adjunct to the standard of care in hospitals and ambulatory surgery centers alike.”

About Barrett’s Esophagus and Esophageal Cancer

Barrett’s Esophagus, often abbreviated as BE, is a condition that results from chronic gastroesophageal reflux disease (GERD), where the lining of the esophagus at the junction of the stomach undergoes significant physiological changes that can often be detected only with thorough screening and surveillance. Chronic GERD affects approximately 5-10% of the population globally, and if left unmanaged can progress to BE without proper surveillance. BE is the only known precursor to esophageal adenocarcinoma (EAC), one of the fastest growing causes of cancer deaths with very poor 5-year survival rates.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real- time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit

Investor Relations – Mauna Kea Technologies NewCap
Thomas Grojean
+33 (0)1 44 71 94 94


Mauna Kea Technologies

This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. All statements other than statements of historical fact included in this press release, including, without limitation, those regarding Mauna Kea Technologies’ financial condition, business, strategies, plans and objectives of management for future operations are forward-looking statements. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties, including the risks set forth in Chapter 3 of the 2020 Universal Registration Document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on June 17, 2021 under number D-21-0566 and the amendment to the 2020 Universal Registration Document filed with the AMF on September 17, 2021, which are both available on the Company's website (, and risks relating the economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. The distribution of this document may, in certain jurisdictions, be restricted by local regulations. Persons who come into possession of this document are required to observe all applicable local regulations relating to this document.

1 DOI:

2 Qumseya, B. et al. Alarming Increase In Prevalence Of Esophageal Cancer And Barrett's Esophagus In Middle-Aged Patients: Findings From A Statewide Database Of Over Five Million Patients Canceer-And-Barretts-Esophagus-In-Middle-Aged-Patients.pdf Accessed July 1, 2022.

3 Randhawa, N. et al. Health Service Utilization Among Patients with Barrett’s Esophagus Using Confocal Laser Endomicroscopy Versus Standard of Care. ENDO 2022.

Source: Mauna Kea Technologies

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.